Although PD‐L1 is expressed in 34.4%−96% of CCa tissues, the objective response rate was only 18% (95% CI, 11 to 28) among cemiplimab‐treated patients with PD‐L1 expression in ≥1% of cells and merely 11% (95% CI, 4 to 25) among those with PD‐L1 expression in <1% of cells.[12] The results of these trials suggest that a small subset of PD‐L1‐positive patients benefit from PD‐1/PD‐L1 inhibitor therapy, underscoring the need for combinatorial approaches involving blockade of the PD‐L1 pathway for cancer therapy. This evidence concerns the gene CD274 and cancer.